Table 3.
Relationships between the severity of canine infection with Leishmania infantum and the anti-saliva antibody response, measured at the time of sampling, approximately 2 months before patent infection, and against transmission intensity (log incidence)
| Severity measure | n (samples) | n (dogs) | LRT χ2 | P |
|---|---|---|---|---|
| Anti-saliva IgG at time of sampling | ||||
| Anti-Leishmania IgG | 206 | 58 | 7.11 | 0.0077 |
| Parasites (bone marrow) | 122 | 53 | 0.00 | 0.95 |
| Parasites (ear skin) | 80 | 40 | 0.03 | 0.86 |
| Clinical score | 195 | 58 | 0.00 | 0.97 |
| Anti-saliva IgG prior to infection | ||||
| Anti-Leishmania IgG | 374 | 58 | 2.79 | 0.095 |
| Parasites (bone marrow) | 214 | 55 | 0.00 | 0.97 |
| Parasites (ear skin) | 152 | 47 | 1.09 | 0.30 |
| Clinical score | 361 | 58 | 0.02 | 0.90 |
| Transmission intensity (log incidence) | ||||
| Anti-Leishmania IgG | 458 | 94 | 0.00 | 0.96 |
| Parasites (bone marrow) | 264 | 81 | 0.05 | 0.82 |
| Parasites (ear skin) | 184 | 63 | 1.51 | 0.22 |
| Clinical score | 439 | 92 | 1.04 | 0.31 |